84
Participants
Start Date
January 23, 2025
Primary Completion Date
April 17, 2026
Study Completion Date
January 17, 2028
INV-9956
INV-9956 is co-administered with dexamethasone and fludrocortisone acetate
RECRUITING
NEXT Oncology, Fairfax
RECRUITING
Next Oncology - Houston, Houston
RECRUITING
UT Health, San Antonio
RECRUITING
Honor Health, Scottsdale
NOT_YET_RECRUITING
Hoag Family Cancer Institute, Newport Beach
NOT_YET_RECRUITING
UC Irvine Medical Center, Orange
NOT_YET_RECRUITING
Summit Cancer Centers, Spokane
NOT_YET_RECRUITING
Liaoning Cancer Hospital, Shenyang
NOT_YET_RECRUITING
Fudan University Shanghai Cancer Center, Shanghai
NOT_YET_RECRUITING
Nanjing Drum Tower Hospital, Nanjing
RECRUITING
Shandong Cancer Hospital, Ji'nan
NOT_YET_RECRUITING
Tianjin Medical University Cancer Institute & Hospital, Tianjin
NOT_YET_RECRUITING
The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou
NOT_YET_RECRUITING
Zhejiang Provincial People's Hospital, Hangzhou
NOT_YET_RECRUITING
The First Affiliated Hospital of Fujian Medical University, Fuzhou
NOT_YET_RECRUITING
Hu'nan Cancer Hospital, Changsha
RECRUITING
He'nan Cancer Hospital, Zhengzhou
Shenzhen Ionova Life Sciences Co., Ltd.
INDUSTRY